- News
- Announcements
Announcements
Current & archive
Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
Within the project Horizon Scanning in Oncology 9 databases are frequently scanned to identify new/emerging oncologic drugs. Every 3 months, these drugs are filtered according to predefined criteria (i.e. in most instances availability of phase III study results) and are then prioritised by an expert panel to identify those therapies for which either a substantial clinical or financial impact can be expected.
Evaluation of individual medical procedures 2014 - Reports
We are pleased to introduce our new reports.
Decision Support Documents 2014:
-
DSD 74: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis
https://eprints.aihta.at/1031 -
DSD 75: Drug eluting stents for the treatment of peripheral artery disease
https://eprints.aihta.at/1032 -
DSD 76: Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases
https://eprints.aihta.at/1030
+2 Updates:
-
DSD 20/ Update 2014: Implantation of endobronchial valves in patients with emphysema
https://eprints.aihta.at/1028 -
DSD 44/1. Update 2014: Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (1st Update 2014)
https://eprints.aihta.at/1029
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 45
Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review
Against the backdrop of an increase in disability pensions due to mental health disorders, the aim of this review was a systematic analysis of the sustainability of inpatient psychiatric/ psychosomatic rehabilitation covering an observation period of at least 12 months after discharge from rehabilitation.
Overall, included studies (1 meta-analysis, 4 RCTs, 2 pre-post studies with, and 14 without a control group) showed similar trends: the improvement between admission and discharge deteriorated to varying degrees during the catamnestic period. Nevertheless, results remained better than at admission, though. In studies on specific aftercare we observed a trend towards an improved stabilization of treatment effects.
Publication: LBI-HTA Project report No.75: https://eprints.aihta.at/1025
Contact: Brigitte Piso
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 43
Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas
Treatment by clinical psychologists: Literature overview on training, methods of treatment and areas of application
In Austria, the ASVG (General Law on Social Security) currently includes clinical-psychological diagnostics, but not treatment by clinical psychologists. The LBI-HTA compiled a literature overview on “treatment by clinical psychologists” on behalf of the Austrian Federal Ministry of Health: Part I includes a comparison of training requirements of clinical psychologists in several countries and analyses Austrian stakeholder views systematically, part II presents a literature overview on treatment methods and indication areas in the international scientific literature.
Publication: LBI-HTA Project report No. 69a: https://eprints.aihta.at/1018
Contact: Nikolaus Patera
Publication: LBI-HTA Project report No. 69b: https://eprints.aihta.at/1019
Contact: Inanna Reinsperger
Hadron Therapy: Proton and carbon ion therapy - a review on clinical evidence of efficacy, ongoing research and reimbursement
Currently, there are about 40 facilities operating worldwide (14 in Europe) that offer hadron therapy. An additional 25 facilities (9 in Europe) are under construction and will go into operation in the coming years. In 2015, the Austrian center, MedAustron, will be opened in Wiener Neustadt. In the next 3–5 years, the capacity in Europe will approximately double. Since a supply-induced demand is to be assumed due to the considerable expansion of capacity in Europe the health policy issues – underlying this report - are: for which indications (tumor entities, stages) is evidence for a better efficacy, resp., fewer side effects through hadron therapy (proton or carbon ion therapy) already available, which clinical trials are currently running, which indications are also mentioned in guidelines, and which indications are reimbursed in other social health insurance countries.
Publication: LBI-HTA Project report No. 72: https://eprints.aihta.at/1021
Contact: Claudia Wild
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
